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Accumulation of amyloid-β (Aβ) in plaques in the brain and in artery walls as 24 
cerebral amyloid angiopathy indicates a failure of elimination of Aβ from the brain with age 25 
and Alzheimer's disease. A major pathway for elimination of Aβ and other soluble 26 
metabolites from the brain is along basement membranes within the walls of cerebral arteries 27 
that represent the lymphatic drainage pathways for the brain. The motive force for the 28 
elimination of Aβ along this perivascular pathway appears to be the contrary (reflection) 29 
wave that follows the arterial pulse wave. Following injection into brain parenchyma, Aβ 30 
rapidly drains out of the brain along basement membranes in the walls of cerebral arteries; 31 
such drainage is impaired in apolipoprotein E ε4 (ApoE4) mice. For drainage of Aβ to occur 32 
in a direction contrary to the pulse wave some form of attachment to basement membrane 33 
would be required to prevent reflux of Aβ back into the brain during the passage of the 34 
subsequent pulse wave. In this study, we show first that apolipoprotein E co-localizes with 35 
Aβ in basement membrane drainage pathways in the walls of arteries. Secondly, we show by 36 
Atomic Force Microscopy that attachment of ApoE4/Aβ complexes to basement membrane 37 
laminin is significantly weaker than ApoE3/Aβ complexes. These results suggest that 38 
perivascular elimination of ApoE4/Aβ complexes would be less efficient than with other 39 
isoforms of apolipoprotein E, thus endowing a higher risk for Alzheimer's disease. 40 
Therapeutic correction for ApoE4/Aβ/laminin interactions may increase the efficiency of 41 
elimination of Aβ in the prevention of Alzheimer's disease. 42 
 43 
Keywords: Apolipoprotein E, perivascular clearance pathways, laminin, atomic force 44 




1. Introduction 47 
A key feature of Alzheimer's disease pathology is the extracellular accumulation of 48 
soluble amyloid-β (Aβ) and of insoluble Aβ as plaques in brain parenchyma and in the walls 49 
of cerebral arteries as cerebral amyloid angiopathy (CAA) [1, 2]. These features indicate that 50 
there is a failure of elimination of Aβ from the brain with increasing age and in Alzheimer's 51 
disease [3]. Mechanisms for elimination of Aβ from the brain include enzymatic degradation 52 
by neprilysin within brain tissue and artery walls; absorption of Aβ into the blood mediated 53 
by low density lipoprotein receptor-1 and elimination by lymphatic drainage along basement 54 
membranes in the walls of cerebral capillaries and arteries [4]. Accumulation of insoluble 55 
fibrillar Aβ in the walls of capillaries and arteries in CAA reflects failure of elimination of 56 
Aβ along lymphatic drainage pathways with age and Alzheimer's disease [5]. 57 
When soluble tracers, including Aβ, are injected into the brain parenchyma, they are 58 
rapidly eliminated along basement membranes of capillaries towards cervical lymph nodes 59 
[6, 7]. The pattern of deposition of Aβ in the walls of capillaries and arteries in human CAA 60 
exactly mirrors the lymphatic drainage pathways defined in experimental tracer studies [5]. 61 
Tracers and Aβ appear to leave the walls of the carotid artery in the neck at the level of 62 
cervical lymph nodes as they drain from the brain to regional lymph nodes in the neck [6, 8]. 63 
Perivascular drainage of Aβ from the brain is impaired with age as shown experimentally and 64 
by the presence of CAA in aging humans [9]. Aβ secreted by amyloid precursor protein 65 
(APP)-transgenic mice harboring the Swedish double mutation driven by a neuron specific 66 
promoter is observed in the perivascular drainage pathways as CAA co-localized with 67 
apolipoprotein E (ApoE) [1]. Furthermore, perivascular drainage of Aβ is impaired in mice 68 
expressing human apolipoprotein E ε4 (ApoE4) suggesting that the risk factor for 69 
Alzheimer's disease in patients possessing the ε4 allele of ApoE may be related to a failure of 70 
elimination of Aβ from brain [10]. 71 
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Studies on the motive force for perivascular drainage of Aβ from the brain suggest 72 
that solutes are driven along basement membranes in the walls of arteries by the contrary 73 
(reflection) wave that follows the pulse wave [11]. In order for this mechanism to function 74 
effectively, some form of attachment of transported material to basement membrane proteins 75 
would be required in order to prevent reflux of material during passage of the pulse wave 76 
itself. If no attachment activity were present, Aβ and other solutes would oscillate within the 77 
basement membrane rather than be driven rapidly out of the brain as has been observed 78 
experimentally. One of the major candidates for performing such attachment activity for Aβ 79 
is ApoE. 80 
ApoE is the predominant lipoprotein in the brain and regulates transport of cholesterol 81 
from astrocytes to neurons [12-14]. Three APOE alleles (ε2, ε3 and ε4) encode the production 82 
of corresponding protein isoforms (E2, E3 and E4).  Binding of Aβ to ApoE has been 83 
proposed as a mechanism by which Aβ is transported across the blood-brain barrier [4] and 84 
levels of ApoE are lower in ApoE4-positive individuals than in ApoE3 carriers [15]. Recent 85 
work has demonstrated minimal direct physical interaction between ApoE and soluble Aβ 86 
within the cerebrospinal fluid [16]. Thus, the role of ApoE in mediating the clearance of Aβ 87 
from the brain remains unresolved.  88 
Since Aβ40 is the predominant type of Aβ found in CAA [17], in the present study we 89 
tested the hypothesis that interactions of Aβ40 with protein components of cerebral vascular 90 
basement membranes, such as laminin, are stronger in the presence of ApoE3 than in the 91 
presence of apoE4. If this hypothesis is substantiated, it would suggest that perivascular 92 
drainage of Aβ in individuals possessing ApoE4 would be less efficient due to defective 93 
attachment of Aβ/ApoE4 complexes to basement membranes during perivascular lymphatic 94 
drainage. This would ultimately lead to failure of elimination of Aβ from the brain and its 95 
deposition in artery walls as CAA. .  96 
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In order to test the hypothesis, we first identified the location of ApoE in relation to 97 
fibrillary Aβ within basement membranes in the walls of arteries in AD. Secondly, we 98 
performed single-molecule force spectroscopy with an atomic force microscope (AFM) in 99 
order to determine the force of attachment between Aβ/ApoE4 complexes and the basement 100 
membrane protein, laminin. We then compared the attachment forces of Aβ/ApoE4 101 
complexes with those of Aβ/ApoE3.  102 
 103 
2. Materials and Methods 104 
2.1 Materials for AFM tip functionalization 105 
Analytical grade materials used for AFM tip functionalization were obtained from 106 
Sigma Aldrich, UK. The following chemicals were used: ethanol, chloroform, ethanolamine 107 
hydrochloride (ethanolamine-HCl), dimethylsulfoxide (DMSO), triethylamine (TEA), 108 
sodium hydroxide (NaOH), sodium cyanoborohydride (NaCNBH3). Aldehyde-PEG-NHS 109 
linker was purchased from Institute of Biophysics, University of Linz, Austria. Human 110 
recombinant laminin-511 was purchased from (BioLamina, Sweden), while human Aβ40 111 
(referred to as Aβ for the rest of the manuscript), human ApoE3 and human ApoE4 were 112 
from Cambridge Bioscience (Cambridge, UK). 113 
 114 
2.2 Immunofluorescence of human tissue 115 
Paraffin sections from 5 cases diagnosed with Alzheimer’s disease from the South 116 
West Dementia Brain Bank, Frenchay Hospital, Bristol were utilised for immunostaining. 117 
Sections of middle frontal gyrus were immunostained with antibodies specific for Aβ42 118 
(clone 21F12, 1:4000), pan-apolipoprotein E (pan-apoE, clone 5F6, 1:2000) provided by Elan 119 
Pharmaceuticals Inc. (USA).  We could not access an antibody specific for Aβ40 that worked 120 
on human tissue, so we used Aβ42, as we know that Aβ42 becomes entrapped in the 121 
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cerebrovascular amyloid deposits [18, 19].  Smooth muscle actin (SMA: clone 1A4, Dako, 122 
UK, 1:100) was used to identify smooth muscle cells in the blood vessel walls. 123 
Immunostaining was performed using the appropriate antigen retrieval methods for 124 
each primary antibody.  For Aβ42, pan-apoE and ApoE E4 sections were pre-treated with 125 
neat formic acid.  Triple immunostaining was detected using AF594 (red, Aβ42) or AF633 126 
(blue, pan-apoE) fluorochromes conjugated with biotinylated secondary antibodies (Life 127 
Technologies, UK) and SMA-FITC (Abcam, UK, 1:200, green), respectively. A Leica SP5 128 
confocal scanning microscope was used for imaging. 129 
 130 
2.3 Atomic force microscope measurements 131 
2.3.1 Functionalization of AFM measuring tips 132 
The AFM silicon nitride tips (MSNL-10, Bruker, UK) were functionalized with the 133 
desired protein following three modification steps: (1) amino functionalization, (2) 134 
modification with aldehyde-PEG-NHS linker, and (3) ligand coupling. AFM cantilevers were 135 
washed in chloroform three times and dried under a stream of nitrogen before tips were 136 
subjected to modification. Amino functionalization was done by esterification with 137 
ethanolamine at room temperature [20]. AFM tips were then placed in a closed container with 138 
the ethanolamine-HCl solution, left overnight, washed three times in DMSO and ethanol and 139 
dried under a stream of nitrogen. Subsequent functionalization steps were performed 140 
following a custom tip modification protocol provided by Agilent Technologies, Inc. [21]. 141 
The PEG linker was immobilized on aminated AFM probes by the NHS ester terminus (step 142 
2). 3.3 mg of aldehyde-PEG-NHS linker was dissolved in 1 ml chloroform, and transferred 143 
into a small glass reaction chamber. 10 l of thriethylamine was added before amino-144 
functionalized AFM tips were immersed into the solution. The chamber was covered to 145 
prevent chloroform evaporation. After 1.5 hours, tips were removed from the solution, 146 
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washed three times in chloroform, and dried under the stream of nitrogen. The use of PEG 147 
spacer, as an intermittent link for biomolecule attachment to the cantilever, provides 148 
important advantages in molecular recognition force spectroscopy [22-26]. The linker is 149 
chemically and physically inert, allowing rapid and free reorientation of biomolecules. The 150 
spacing between molecule and the tip reduces the likelihood of molecules being crushed 151 
during the probe-surface contact. Non-linear elastic properties of PEG make it easy to 152 
discriminate between the non-specific and specific interaction events. 153 
Proteins (Laminin, ApoE3, or ApoE4) were immobilized on AFM probes using the 154 
amine-amine reactive linker aldehyde-PEG-NHS. A sheet of parafilm was pressed into a 155 
glass petri dish. AFM cantilever chips were set onto the film in a circular “wagon wheel” 156 
pattern so that the tips were pointed upward and inward. 10 - 30 l of the protein solution was 157 
applied onto the cantilevers. The proteins were allowed to react for one hour to couple via 158 
intrinsic amino groups to the aldehyde-function of the PEG linker on the tip.  After one hour, 159 
5 l of 1M ethanolamine was added to the protein solution drop to inactivate unreacted 160 
aldehyde groups.  161 
 162 
2.3.2 Substrate preparation for AFM experiments 163 
Substrates for AFM experiments were prepared as follows: 20 l of protein solution, 164 
i.e. Aβ, ApoE3, ApoE4, or complexes of ApoE3 + Aβ (1:1 molar ratio), and ApoE4 + Aβ 165 
(1:1 molar ratio). Complexes were left to react at 4°C for 1 hour.  Solutions were added onto 166 
a freshly cleaved mica (Agar Scientific, UK) substrate which was already inserted into a 167 
liquid cell. 100 l of dH2O were added to a cell. Proteins were left to adsorb to the substrate 168 
for 30 min. The mica substrate was washed with water to ensure that only adsorbed proteins 169 
remained on the substrate.  170 
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Aβ has a tendency to form large aggregates with time [27]. To maintain the solubility 171 
state of Aβ, fresh protein was deposited on the mica every 4 hours, and a new functionalized 172 
AFM tip was used in the experiments. Images of Aβ were captured immediately after 173 
deposition and before the possible A rearrangement, i.e. after 4 hours. No Aβ agglomeration 174 
in fibrillar form was observed on the mica during any stage of the experiment. 175 
 176 
2.3.3 Single molecule force spectroscopy experiments 177 
Sample imaging and molecular force spectroscopy experiments were performed in 178 
water using Agilent 5500 Scanning Probe Microscopy, MAC III, Agilent Technologies, US. 179 
Images were acquired using the same cantilevers in contact mode. Actual constant values of 180 
AFM cantilevers were measured in liquid using a built-in thermal noise method [28] before 181 
each experimental set. Determined force constant was used to calculate actual loading and 182 
unbinding forces. Force spectroscopy data were acquired at loading rates ranging from 3000 183 
– 160000 pN/s, corresponding to retraction rates of 0.08 – 3 m/s. At least 1000 curves were 184 
recorded for each experimental condition. The following tip-substrate pairs were measured: 185 
Laminin - Aβ, Laminin - ApoE3, Laminin - ApoE4, or Laminin (on the tip), against 186 
complexes of ApoE3 + Aβ, or ApoE4 + Aβ. In a separate run of experiments, we used 187 
ApoE3 on the tip and Aβ as a substrate, or ApoE4 on the tip and Aβ as a substrate. All 188 
experiments were repeated independently three times, allowing 2 – 3 weeks between each 189 







2.3.4 Data Analysis 195 
PicoView 1.10 and PicoImage (Agilent Technologies, US) software were used for 196 
data acquisition and image analysis, respectively. Force curves were analysed using PUNIAS 197 
macro software (http://punias.voila.net/).  From several hundred single molecule unbinding 198 
events, the probability density function (PDF) was constructed as described in [29, 30]. The 199 










𝑖=1        (1) 201 
where p(F) is the estimate for the PDF that the bond will break at force F, i and i are 202 
rupture force and accuracy respectively, with the sum running over all N (several hundred in 203 
our case) rupture events. PDF gives the statistical distribution of rupture forces (termed as 204 
“unbinding force”). The most probable unbinding force was then determined by fitting Gauss 205 
function to the estimated PDF using Origin analytical software.  206 











)       (2) 209 
where kBT is the thermal energy (4.1 pNnm at room temperature), koff  (1/s) is the dissociation 210 
rate constant, x is a length scale in nm describing the separation of the receptor-ligand pair 211 
between the bound and the transition state, r (pN/s) is the loading rate. The parameters x and 212 






3. Results 217 
3.1 Immunofluorescence 218 
Aβ42 was observed in the walls of blood vessels from brains with Alzheimer’s 219 
disease (Figure 1). ApoE was also observed in the walls of arteries, between the layers of 220 
smooth muscle cells and co-localized with Aβ42 (Figure 1). 221 
 222 
 
Figure 1. Triple immunostaining for Amyloid-β (Aβ) 1-42 (red), pan-Apolipoprotein E 223 
(ApoE) (blue), smooth muscle actin (green) of a leptomeningeal artery of a case of 224 
Alzheimer’s disease. Aβ42 co-localizes with apolipoprotein E (magenta) adjacent to smooth 225 
muscle actin, suggesting that Aβ and ApoE co-localize in the basement membranes of the 226 
smooth muscle tunica media. Confocal Leica SP5 image, a 63 objective was used, scale bar 227 





3.2 Molecule force spectroscopy 231 
Force-spectroscopy experiments were performed to study the reciprocal influence of 232 
different isoforms of ApoE and Aβ on their binding interactions with laminin. The protein 233 
adsorption on the mica, its conformation and size was investigated by contact-mode AFM 234 
imaging in liquid. As an example, Figure 2a shows Aβ assemblies on the substrate. 235 
Scratching away adhered molecules with higher force, gave 2 x 2 m area of bare (or almost 236 
bare) mica (Figure 2b). This simple experiment further confirmed protein presence on the 237 
surface. Furthermore, it also indicates that Aβ is in the form of small oligomers (molecules 238 
were of about 5 ± 0.5 nm in height) instead of fibrils as described in Refs. [32, 33] or large 239 
agglomerates. ApoEs were measured to be 15 ± 2 nm in height, and complexes of Aβ with 240 





Figure 2. Contact-mode AFM images in liquid of A deposited on mica (a). The presence of 243 
protein molecules was proved by scratching the proteins with higher force in an area of 2 x 2 244 




To study specific binding of tip-bound protein to mica-bound protein by force 247 
spectroscopy, the functionalized tip was repeatedly brought into contact with the protein and 248 
retracted at constant load and velocity. Figure 3a shows an example of typical force-distance 249 
curve with a single recognition event.  The cycle starts at a point 1 which corresponds to the 250 
free cantilever, when the tip is far away from the substrate. The probe comes in contact with 251 
the surface at point 2, and bends further until it reaches point 3. During unloading, the 252 
cantilever relaxes to reach point 4, which usually corresponds to the point of contact. If there 253 
is specific interaction between biomolecules, the unloading curve follows the pass through 254 
steps 5-7. The cantilever begins to deflect in a non-linear fashion. This characteristic 255 
signature peak results from the stretching of the polymer linker, and identifies specific ligand-256 
receptor binding. The force increases until enough energy is transferred to break the bond 257 
(points 6 to 7), where FU indicates an unbinding force in pN. The tip and substrate are 258 
completely separated at this point. To ensure that the measured unbinding event is specific to 259 
the ligand-receptor interaction, the force-displacement curves between the functionalized tip 260 
and clean mica in an aqueous environment were recorded. As expected, all loading and 261 












Figure 3. Example of force-displacement curves obtained during single molecule force 268 
spectroscopy experiments for an experimental set tip - ApoE3, substrate - A. (a) Typical 269 
force-displacement cycle with a single specific interaction. See text for explanation. (b) 270 
Control - no interaction between biomolecules attached to the tip and clean mica substrate.  271 
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Force-displacement cycles were analysed as described in materials and methods. The 272 
most probable unbinding force and binding probabilities (BP) were calculated using 273 
Equations 1 and 2. The FU and binding probability results for various ligand-receptor pairs 274 
recorded at 1 Hz with 100-300 nm amplitude, resulting in loading rates from 15,000 – 70,000 275 
pN/s, are presented in Figure 4. The unbinding forces between laminin and ApoE3 and 276 
between laminin and apoE4 are the same (450 ± 50 pN), Figure 4a. However, when Aβ was 277 
added to ApoE, less energy was required to detach a laminin molecule from any of the 278 
complexes (~ 270 ± 25 pN). It was also noted that unbinding of ApoE3 and ApoE4 from Aβ 279 
occurred with similar force of ~ 270 ± 25 pN, while laminin bonded to Aβ at forces of 350 ± 280 
35 pN.  281 
The binding probability was defined as the probability of recording an unbinding 282 
event in a force-distance cycle in relation to all recorded cycles, i.e. how many curves with 283 
specific recognition were recorded out of 1000 measured cycles. Results of binding 284 
probability for various tip-substrate interaction are given in Figure 4b, where BP of 1 would 285 
correspond to 100%, 0.3 = 30%, and so on. Laminin tended to bind more frequently to 286 
ApoE3, Aβ, and Aβ+ApoE3 complex with a probability of ~ 30 ± 3%. BP of laminin to 287 
ApoE4 was calculated to be 15 ± 1.5 %, and for Aβ+ApoE4 complex it was 22 ± 2 %. Very 288 
few binding events were recorded between ApoE3/4 (tip) and Aβ (substrate), where 7% of all 289 
specific recognition curves were recorded for ApoE4 - Aβ interaction, and 2% for ApoE4 - 290 
Aβ (Figure 4b, grey columns). Aβ was always immobilized on the mica, and so the protein 291 
orientation might have been such that binding sites were directed towards the substrate 292 
leaving very few sites exposed. In this case, ApoEs attached to the AFM tip would hardly 293 
bind to Aβ. If this were the case, similar results should be observed between laminin (tip) and 294 
Aβ (substrate). But experimental binding probability between laminin and Aβ was 30%, and 295 







Figure 4. (a) Most probable unbinding force, FU, and (b) specific binding probability for 297 
various tip-substrate pairs. Results are given for force-displacement cycles obtained at 1 Hz 298 
with 100 – 300 nm amplitude. 299 
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3.3 Kinetic constants and affinities 300 
The parameters of prime interest in describing any biological ligand-receptor system 301 
are the rates of spontaneous association (or on-rate, kon), dissociation (off-rate, koff), and their 302 
ratio the dissociation constant (also known as affinity) KD = koff/kon which describes the 303 
equilibrium behaviour. To calculate association and dissociation constants, molecular force 304 
spectroscopy experiments were carried out in a range of loading rates from 3000 – 160000 305 
pN/s, and tip-substrate contact times 0.001 – 0.5 s. To estimate kinetic on-rate constant, kon, 306 
from single molecule unbinding force measurements, it is necessary to determine interaction 307 
time  (the time required for half maximal recognition probability) and effective 308 
concentration ceff, for kon = ( ceff)-1[23, 34, 35]. The effective concentration is described as a 309 
number of binding receptor molecules within the effective volume accessible for free 310 
equilibrium interaction, and is explained in detail elsewhere [23, 34, 35]. The interaction time 311 
was calculated from the binding probability at different encounter times by fitting P = A(1 – 312 
exp( – (t – t0)/)) (where t0 is a lag time, A is the maximum observable  binding probability) 313 
[34]. An example is shown in figure Figure 5(a) for ApoE4 interaction with Aβ.  314 
Furthermore, according to single barrier theory, the unbinding force rises linearly with 315 
respect to logarithmically increasing loading rate [30, 36, 37]. A linear increase of the most 316 
probable unbinding force versus loading rate was observed for all measured interactions. As 317 
an example, Figure 5(b) demonstrates unbinding force dependence on loading rate for ApoE4 318 
interaction with Aβ. The off-rate is determined from the linear fit extrapolated at zero force 319 
[36, 37]. The slope of the fit corresponds to kT/x in Equation 2. The intercept at zero force 320 














Figure 5. Kinetics of ligand-receptor binding. (a) Binding probability as a function of contact 323 





Calculated rate constants and affinities for all AFM measured ligand-receptor pairs is 327 
given in Table 1. The results for all AFM measurements demonstrate that Aβ + ApoE3 328 
complex has a stronger binding to laminin than Aβ + ApoE4. 329 
 330 
Table 1. Association (kon) and dissociation (koff) rates, and affinity (KD) obtained by AFM. 331 
The lower KD value indicates stronger interaction. Aβ + ApoE3 has a stronger binding to 332 
laminin, compared to Aβ + ApoE4. 333 
Tip Substrate kon (1/Ms) koff (1/s) KD (1/M) 
ApoE3 A 2.26 x104 0.01091 4.83 x10-7 
ApoE4 A 1.08 x105 0.01025 9.45 x10-8 
Laminin A 1.10 x106 0.01241 1.13 x10-8 
ApoE3 2.08 x106 0.00541 2.60 x10-9 
ApoE4 1.07 x106 0.00527 4.94 x10-9 
A + ApoE3 1.23 x106 0.018 1.46 x10-8 
A + ApoE4 1.46 x105 0.02224 1.52 x10-7 
 334 
 335 
4. Discussion 336 
The results of the present study have shown that ApoE and Aβ42 co-localize within 337 
basement membranes of the cerebral vasculature that form the elimination pathways for Aβ  338 
from the brain, consistent with Aβ being eliminated from the brain as a complex with ApoE 339 
[12]. Electron paramagnetic resonance spectroscopy study of the interactions between 340 
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apolipoprotein E and oligomers of Aβ40 demonstrate that ApoE3 has a higher affinity for 341 
Aβ40 compared to ApoE4 [38]. Our own data show stronger binding of Aβ40 to ApoE4 342 
compared with ApoE3. Other studies have shown that ApoE4 binds Aβ with higher affinity 343 
compared with ApoE3 and this is reversed when using lipidated forms of ApoE [39, 40] . 344 
More recently, using HEK-293 cells expressing ApoE3 or ApoE4 and Aβ42 it was shown 345 
that the interactions between ApoE4 and Aβ42 are weaker compared with ApoE3- Aβ42, 346 
with ApoE3-Aβ complexes saturable and dependent on Aβ concentrations [41]. We did not 347 
use Aβ42 in this study, but Aβ40, the type predominantly found in the walls of blood vessels 348 
and we used a ratio of Aβ-ApoE of 1:1, as our aim was to concentrate on the interaction of 349 
the Aβ40-ApoE3/4 complexes with the laminin component of the basement membranes.   350 
We found that the complex Aβ + ApoE4 interacted with laminin less avidly (KD = 351 
1.52 x 10-7 M-1) compared to the complex Aβ + ApoE3 (KD = 1.46 x 10-8 M-1). These results, 352 
together with our mathematical modelling studies (4), suggest that the perivascular clearance 353 
of soluble Aβ along cerebrovascular basement membranes may be slower in ApoE4 carriers, 354 
compared to ApoE3 carriers, due to a lack of biophysical interaction between Aβ and 355 
individual components of basement membranes (in this case laminin). Less efficient 356 
biophysical interaction between Aβ + ApoE4 and basement membrane proteins, such as 357 
laminin would mean that there would be weaker attachment to the basement membrane 358 
during passage of the pulse wave and ApoE4-Aβ complexes may remain in the extracellular 359 
spaces as seeds for plaques, promoting inflammation [42, 43]. Thus Aβ + ApoE4 would not 360 
be driven out of the brain along perivascular pathways as efficiently as Aβ + ApoE3. This 361 
may be an important factor in the failure of elimination of Aβ from the brain in ApoE4 362 
carriers and the consequent accumulation of Aβ in the brain and artery walls and the 363 
development of Alzheimer's disease. Apolipoprotein E appears to be located in the 364 
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perivascular compartment of blood vessels in the human brain and co-localizes with Aβ in 365 
Alzheimer’s disease [44]. 366 
Elimination of Aβ from the brain in Alzheimer's disease has been the major objective 367 
of a number of Aβ immunotherapy trials. Although in many patients insoluble plaques of Aβ 368 
are cleared from cortical areas, an increase in the severity of CAA has been reported [45].  369 
This suggests that Aβ cleared from the brain parenchyma becomes entrapped in the 370 
perivascular drainage pathways with the ultimate failure of elimination of Aβ from the brain 371 
[45]. Recently it has also been demonstrated that Aβ immunotherapy was associated with 372 
redistribution of ApoE from cortical plaques to cerebral vessel walls, mirroring the altered 373 
distribution of Aβ 42 from the plaques towards the walls of blood vessels [46], consistent 374 
with ApoE/Aβ travelling as a complex. Complications are associated with Aβ 375 
immunotherapy, designated Amyloid Related Imaging Abnormalities (ARIA) [47].  Evidence 376 
suggests that ARIAs are due to vascular alterations, including increased severity of CAA. As 377 
ARIAs occur more frequently in AD patients who are APOE ε4 carriers than non-ε4 carriers, 378 
the differential binding of Aβ/apoE E3 and E4 to laminin demonstrated in this study may be 379 
relevant to the causation of ARIA as Aβ is being removed from the brain.  380 
 381 
5. Conclusions 382 
The results of this study add to our knowledge of the dynamics of perivascular 383 
drainage and its importance for the elimination of Aβ from the brain. Accumulation of 384 
soluble and insoluble Aβ in brain parenchyma and in artery walls occurs with advancing age 385 
and is enhanced in those possessing the ApoE4 allele. Experimental and theoretical data 386 
indicate that vascular pulsations are the driving force for perivascular elimination of Aβ with 387 
the contrary (reflection) wave driving Aβ and other solutes out of the brain in the reverse 388 
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direction to blood flow [11]. Reduction in the amplitude of the pulse wave may occur as 389 
arteries stiffen with age and arteriosclerosis, thus reducing the motive force for the 390 
perivascular drainage of Aβ and other solutes from the brain. 391 
The present study suggests that the presence of ApoE4 further reduces the efficiency 392 
of perivascular elimination of Aβ due to reduced attachment of ApoE4/Aβ complexes to 393 
basement membranes in the drainage pathway, although the type of Aβ and the lipidation 394 
status of ApoE are crucial [12]. Such reduced attachment may allow oscillation of Aβ within 395 
the basement membrane during passage of the pulse wave and thus impair the progress of Aβ 396 
out of the brain along the perivascular pathways. 397 
Therapeutic strategies that optimise attachment of soluble metabolites to basement 398 
membrane proteins may also optimise elimination of those metabolites from the brain. The 399 
present study has established a principle that could be developed in the future to test therapies 400 
for the prevention of Alzheimer's disease, based on manipulating the Aβ-ApoE interactions 401 
with basement membrane proteins. 402 
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